If you have seen BPC-157 or TB-500 mentioned online and wondered why you cannot get them from a pharmacy, FDA’s own review is the best place to start. In July 2026, the agency put seven peptides in front of an advisory committee, and its staff proposed that none of them be added to the compounding list. Here is what the agency’s briefing documents say about the evidence.
What FDA reviewed
Compounding pharmacies can only use certain bulk ingredients. An ingredient with no U.S. drug monograph and no place in an approved drug has to be on FDA’s “503A bulks list.” Before adding a substance to that list, FDA weighs four things: how well it is characterized chemically, safety issues, the evidence that it works, and its history of use in compounding.[1]
On July 23 and 24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to discuss seven peptides for that list: BPC-157, KPV, TB-500, and MOTS-c on the first day, then emideltide, epitalon, and Semax on the second. For each one, FDA staff proposed that it not be included.[1] The committee gives advice only. FDA stated it would not issue a final determination until the committee’s input was considered and all reviews were finalized.[1] The committee voted 8-6, with one abstention, in favor of adding BPC-157 to the list, as reported by ABC News. ABC also reported that the vote still needs sign-off from the agency.[4] FDA’s meeting page describes the BPC-157 use the committee evaluated as ulcerative colitis and lists no vote record (checked 2026-10-14).[5] Check FDA’s advisory committee page for any later FDA action. For other small human studies of BPC-157 and what is known about its use, see BPC-157, the ‘Wolverine’ Peptide: Documented Use Is Rising, but Human Safety Data Is Thin.
What FDA found about BPC-157
FDA’s review of BPC-157 focused on ulcerative colitis, one of the uses proposed in the nomination. It found a lack of evidence that BPC-157 works for that condition. The only human trial for that condition that it located was a single small study reported as a meeting abstract, and FDA said the abstract had too little detail, and the study was too exploratory, to draw conclusions.[2]
Most of the other research was in animals. FDA noted that studies in rats reported protective effects on the gut and liver, but it called the biology hard to judge because dose-response relationships and molecular targets have not been established.[2]
On safety, FDA found no studies that gave BPC-157 to people by the routes proposed in the nominations: by mouth, by injection under the skin, as a nasal spray, or on the skin. It found two studies using a rectal enema for up to two weeks, with no serious adverse events reported but limited safety monitoring. FDA’s search also turned up a few other very small human studies, including injections into a knee or the bladder and an intravenous infusion in two healthy volunteers, and said the studies were short, with small samples and limited safety data. FDA concluded there is not enough clinical safety information to describe the safety profile, and it raised concern that injected or nasal peptides can trigger immune reactions, especially when impurities or clumped peptide are present. It also noted that no approved product containing BPC-157 exists in any country.[2]
What FDA found about TB-500
TB-500 was nominated for wound healing. FDA found no information in the medical literature where TB-500 was given to patients to treat any disease or condition, including wound healing, and concluded there was a lack of evidence to evaluate whether it works. It also found no human studies of how the body absorbs or processes it.[3] FDA raised the same immune-reaction concern for injectable forms.[3]
The takeaway
Easier legal access to a peptide would not make it proven. FDA’s review of BPC-157 for ulcerative colitis found one small, exploratory human study; other small human pilots exist for other uses. For TB-500, FDA found no studies in patients for the use it evaluated. Even if rules change, a pharmacy label would speak to who made the product, not to whether it helps. If you are thinking about taking a peptide for a health condition, talk with your clinician first.
References
↑︎ U.S. Food and Drug Administration. FDA briefing document: Pharmacy Compounding Advisory Committee (PCAC) meeting, July 23-24, 2026 (introduction and points to consider). URL: https://www.fda.gov/media/193342/download
↑︎ U.S. Food and Drug Administration. FDA briefing document for BPC-157-related bulk drug substances (BPC-157 free base and BPC-157 acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. URL: https://www.fda.gov/media/193343/download
↑︎ U.S. Food and Drug Administration. FDA briefing document for TB-500-related bulk drug substances (TB-500 free base and TB-500 acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. URL: https://www.fda.gov/media/193349/download
↑︎ Salzman S, Kekatos M. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. ABC News. July 23, 2026. URL: https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891. Finding used: reported an 8-6 vote with one abstention in favor of adding BPC-157; the vote needs sign-off from the agency. The vote count is as reported by ABC News.
↑︎ U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. URL: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026. Finding used: advisory committees make non-binding recommendations; the BPC-157 use evaluated was ulcerative colitis.
Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.
Leave a Reply